ProfileGDS5678 / 1446812_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 52% 51% 60% 48% 50% 51% 59% 51% 50% 51% 50% 51% 53% 52% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2965152
GSM967853U87-EV human glioblastoma xenograft - Control 23.2168351
GSM967854U87-EV human glioblastoma xenograft - Control 33.5848260
GSM967855U87-EV human glioblastoma xenograft - Control 43.0799548
GSM967856U87-EV human glioblastoma xenograft - Control 53.1541350
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3419851
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6348359
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.2279951
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1672250
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.2002751
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2019650
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.180251
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.2997953
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2426952